Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boers, M
Right arrow Articles by van der Linden, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boers, M
Right arrow Articles by van der Linden, S.
Annals of the Rheumatic Diseases 2003;62:842-845
© 2003 by BMJ Publishing Group & European League Against Rheumatism


EXTENDED REPORT

Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

M Boers 1, M T Nurmohamed 2, C J A Doelman 3, L R Lard 4, A C Verhoeven 5, A E Voskuyl 6, T W J Huizinga 4, R J van de Stadt 7, B A C Dijkmans 8, Sj van der Linden 9

1 Department of Clinical Epidemiology and Biostatistics, Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
2 Department of Rheumatology, VU University Medical Centre, Jan van Breemen Institute, Amsterdam, The Netherlands
3 Central Laboratory, Medisch Spectrum Twente, Enschede, The Netherlands
4 Department of Rheumatolgy, Leiden University Medical Centre, Leiden, The Netherlands
5 Department of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
6 Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
7 Jan van Breemen Institute, Amsterdam, The Netherlands
8 Department of Rheumatology, VU University Medical Centre, Jan van Breemen Institute, Slotervaart Hospital, Amsterdam, The Netherlands
9 Department of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands

Correspondence to:
Correspondence to:
Dr M T Nurmohamed, Department of Rheumatology, VU University Medical Centre, Room 4A42, PO Box 7057, Amsterdam, The Netherlands;
mt.nurmohamed{at}vumc.nl

Background: Glucocorticoids induce hypercholesterolaemia, a cardiovascular risk factor, in patients with diseases other than rheumatoid arthritis (RA), but the data in RA are contradictory.

Objective: To determine the effects of antirheumatic treatment, including prednisolone (combination) therapy on total and high density lipoprotein (HDL) cholesterol levels in RA, taking disease activity into account.

Methods: HDL cholesterol and total cholesterol levels were determined in:(a) established RA (b) two cohorts with early active RA, (c) a previously conducted 56 week trial among patients with early RA comparing the value of intensive combination therapy (that included glucocorticoids) with sulfasalazine alone (COBRA trial).

Results: In established RA total cholesterol levels were only slightly raised, irrespective of disease activity. However, HDL cholesterol was significantly higher in patients in remission than in patients with active disease. In contrast, in active early RA at baseline total cholesterol was low normal: between 4.6 and 5.1 mmol/l in the different populations. The level of HDL cholesterol was highly dependent on the duration of storage. In both COBRA groups total cholesterol increased by a mean of 0.6 mmol/l. HDL cholesterol increased by more than 50% after treatment, leading to an improvement of the total cholesterol/HDL ratio (atherogenic index). This increase (and index improvement) was much more rapid in the group receiving combination treatment. A similar pattern was seen in the 2001 cohort with early RA. In all the groups with active disease HDL and total cholesterol levels correlated inversely with disease activity.

Conclusion: In established, but especially in early RA, disease activity is accompanied by atherogenic lipid levels. This dyslipidaemia can be rapidly reversed by aggressive antirheumatic treatment including glucocorticoids.


Keywords: rheumatoid arthritis; lipid profile; cholesterol; disease activity

Abbreviations: ACR, American College of Rheumatology; DAS, disease activity score; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HDL, high density lipoprotein; RA, rheumatoid arthritis




This article has been cited by other articles:


Home page
Ann Rheum DisHome page
W G Dixon and D P M Symmons
What effects might anti-TNF{alpha} treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF{alpha} in cardiovascular pathophysiology
Ann Rheum Dis, September 1, 2007; 66(9): 1132 - 1136.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M J L Peters, M Vis, V P van Halm, G J Wolbink, A E Voskuyl, W F Lems, B A C Dijkmans, J W R Twisk, M H M T de Koning, R J van de Stadt, et al.
Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis
Ann Rheum Dis, July 1, 2007; 66(7): 958 - 961.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
L. Fardet, J. Cabane, A. Kettaneh, C. Lebbe, and A. Flahault
Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome
Rheumatology, July 1, 2007; 46(7): 1102 - 1106.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
T. M Farragher, M. Lunt, D. K Bunn, A. J Silman, and D. P M Symmons
Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register
Ann Rheum Dis, April 1, 2007; 66(4): 486 - 492.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
V P van Halm, M M J Nielen, M T Nurmohamed, D van Schaardenburg, H W Reesink, A E Voskuyl, J W R Twisk, R J van de Stadt, M H M T de Koning, M R Habibuw, et al.
Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis
Ann Rheum Dis, February 1, 2007; 66(2): 184 - 188.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. E. Voskuyl
The heart and cardiovascular manifestations in rheumatoid arthritis
Rheumatology, October 1, 2006; 45(suppl_4): iv4 - iv7.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Ines, E J P de Koning, F Buttgereit, M Cutolo, H Capell, et al.
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
Ann Rheum Dis, March 1, 2006; 65(3): 285 - 293.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
R Gerli and N J Goodson
Cardiovascular involvement in rheumatoid arthritis
Lupus, September 1, 2005; 14(9): 679 - 682.
[Abstract] [PDF]


Home page
Rheumatology (Oxford)Home page
M. Pisu, N. James, S. Sampsel, and K. G. Saag
The cost of glucocorticoid-associated adverse events in rheumatoid arthritis
Rheumatology, June 1, 2005; 44(6): 781 - 788.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
J W J Bijlsma, M Boers, K G Saag, and D E Furst
Glucocorticoids in the treatment of early and late RA
Ann Rheum Dis, November 1, 2003; 62(11): 1033 - 1037.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 BMJ Publishing Group Ltd & European League Against Rheumatism